Instituto Butantan to Produce CoronaVac Vaccine in Brazil, an Industrial Info Market Brief

Brazilian state company Instituto Butantan, with the financial support of Fundacao Butantan, is investing about $31 million at its Sao Paulo plant to produce 1.2 million units of the CoronaVac vaccine for COVID-19. Plans are to kick off the project in January and complete it during the last quarter of 2021. The latest news published by the Wall Street Journal confirmed that Brazil is the first country to complete Phase 3 trials of the Chinese COVID-19 vaccine, and as it is showing effectiveness, Instituto Butantan will request the proper emergency use authorization by the Brazilian health authority, Anvisa.